Webinars, Pharmaceutical

Aptar Pharma provides guidance on FDA regulatory framework for OINDPs

In April 2018, the FDA released guidance on metered dose inhaler and dry powder inhaler product – quality considerations, hot on the heels of finalized FDA guidance for combination products issued in January 2017, where a combination product is defined as one composed of two or more different types of medical products. This webinar provides practical insights into how to navigate FDA expectations relating to NDA and ANDA submissions, in the context of the current guidance, in the development of Orally Inhaled and Nasal Drug Products (OINDPs). Insights on optimal approaches to help secure approval in this changing and challenging regulatory landscape are shared.

September 18, 2018 5:00 PM London / 12:00 PM New York 1 Hour
Watch the Webinar
Presented by Badre Hammond Wendy Bolf
18 Sep 2018

Presented By

Badre Hammond

VP Commercial Operations, Aptar CSP

Badre Hammond’s background is in Biochemistry with 14 years’ experience in pharmaceutical product development with focus on nasal and pulmonary drug delivery systems. Mr. Hammond has broad experience in managing development of novel drug product programs for the pharmaceutical market from formulation development, pre-clinical, CMC, to clinical phase.

Wendy Bolf

Regulatory Affairs Manager

Wendy Bolf’s expertise is in Regulator Affairs with a BASc in Chemical Engineering and she has specialized in drug delivery systems for 20+ years.  Mrs. Bolf has headed up the regulatory affairs department and has developed strategies for Aptar’s Drug Master Files and directly supported numerous FDA inspections on site as well as Type C meetings with FDA in order to gain approval of strategies including CMC sections, approval of INDs, NDAs, and ANDAs – mostly specializing in nasal and pulmonary drug delivery.  Mrs. Bolf has been involved from the device regulatory side in supporting the approval of dozens of drug products (NDA and ANDAs) on the US market. In her current role, she is involved in Combination Product regulatory strategies for Aptar Pharma.

Start a Project With Us

We Thrive on Transforming Ideas into Opportunities – Let Yours be Next.

Contact a Pharma Expert

Request Access

Close

Requesting access to Aptar Pharma provides guidance on FDA regulatory framework for OINDPs.

  • This field is for validation purposes and should be left unchanged.

How Can We Help?

Back To Top